Edwards Lifesciences Corp (EW-N) Stock Predictions - Stockchase
WATCH LIST
7
Edwards Lifesciences Corp (EW-N)

ON STOCKCHASE SINCE Jul 2005

biotechnology/pharmaceutical

Edwards Lifesciences Corp

EW-N

3 watching          
Join the Discussion

Edwards Lifesciences Corp (EW-N) SAVE Mar, 20, 2019, 6:10 am

189.36 1.53 (0.8%)

About Edwards Lifesciences Corp (EW-N)

Edwards Lifesciences is an American medical equipment company specializing in artificial heart valves and hemodynamic monitoring. More at Wikipedia

What the experts are saying about EW-N



  • All
  • Filtered
Signal Opinion Expert
PAST TOP PICK
(A Top Pick Mar 19/18, Up 22%) He owns this through the IHI ETF. Their catheter device accounts for 60% of revenue and results in less-invasive surgeries which results in higher patient turnover in hospitals (which are expensive). This is better for patients and hospitals. They continue to take market share.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
(A Top Pick Mar 19/18, Up 22%) He owns this through the IHI ETF. Their catheter device accounts for 60% of revenue and results in less-invasive surgeries which results in higher patient turnover in hospitals (which are expensive). This is better for patients and hospitals. They continue to take market share.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Cameron Hurst

Chief Inve, Equium Capital Manag...

Price Price
$170.960
Owned Owned
Yes

PAST TOP PICK
(A Top Pick Feb 08/18, Up 37%) A high-quality holding, who's business is less evasive surgery technology. They have massive market share in the space. Lots of spending by hospitals will go into this. You have to accept it will be volatile at times.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
(A Top Pick Feb 08/18, Up 37%) A high-quality holding, who's business is less evasive surgery technology. They have massive market share in the space. Lots of spending by hospitals will go into this. You have to accept it will be volatile at times.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Cameron Hurst

Chief Inve, Equium Capital Manag...

Price Price
$170.580
Owned Owned
Yes

DON'T BUY

When it came down to his model price it was the only buying opportunity there was in the last eight years.  He loves the company.  Model price is $99.94, a 30% premium that it is trading at.  He can only wish for a pull back.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

When it came down to his model price it was the only buying opportunity there was in the last eight years.  He loves the company.  Model price is $99.94, a 30% premium that it is trading at.  He can only wish for a pull back.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Brian Acker, CA

Chief Exec, Acker Finley Inc....

Price Price
$143.800
Owned Owned
Unknown

TOP PICK

Trans-catheter aortic valve replacement is their business, a best in class valve that's been taken up widely in hospitals around the world. This market will double in three years, and they are the big player. (Analysts' target of $142.80)

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Trans-catheter aortic valve replacement is their business, a best in class valve that's been taken up widely in hospitals around the world. This market will double in three years, and they are the big player. (Analysts' target of $142.80)

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Cameron Hurst

Chief Inve, Equium Capital Manag...

Price Price
$139.400
Owned Owned
Yes

TOP PICK

Valve replacement.  They have trans catheter valve replacements.  It is done in the least invasive way that the medical space has come up with.  It is all very positive.  They are well placed in a growing part of the healthcare market.  It is expected to double by 2021.  (Analysts’ target: $142.).

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Valve replacement.  They have trans catheter valve replacements.  It is done in the least invasive way that the medical space has come up with.  It is all very positive.  They are well placed in a growing part of the healthcare market.  It is expected to double by 2021.  (Analysts’ target: $142.).

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Cameron Hurst

Chief Inve, Equium Capital Manag...

Price Price
$123.780
Owned Owned
Yes

COMMENT

Very focused on cardiovascular and ICU. The great thing about this is that the demand is very inelastic, so you get the unit demand independent of the economic cycle, a good solid demand. Also, they are innovators and have good research and good product flow on their own and have been smart acquirers.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Very focused on cardiovascular and ICU. The great thing about this is that the demand is very inelastic, so you get the unit demand independent of the economic cycle, a good solid demand. Also, they are innovators and have good research and good product flow on their own and have been smart acquirers.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Dr. Richard Eva

Head of He, SSR...

Price Price
$96.050
Owned Owned
Unknown

TOP PICK
Primarily involved in cardiovascular products. Half the business is in heart valve therapy with about 45% of market share. Have some new products that could create new markets for them and this hasn't been priced into the stock.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Primarily involved in cardiovascular products. Half the business is in heart valve therapy with about 45% of market share. Have some new products that could create new markets for them and this hasn't been priced into the stock.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Phil Taller

VP of Inv, Mackenzie Investment...

Price Price
$42.230
Owned Owned
Yes

Showing 1 to 7 of 7 entries
Successfully Saved Company
Successfully Saved Company